The Mesothelioma Center News
Johnson & Johnson Preparing $3.9 Billion for Talc Settlements
- by Tim Povtak
- Legislation & Litigation
- Feb 24, 2021
Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory filing this week with the Securities and Exchange Commission in Washington D.C. The…
Read More
Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
- by Tim Povtak
- Research & Clinical Trials
- Feb 23, 2021
Thoracic surgeon Dr. Bryan Burt at the Baylor College of Medicine wants to better identify which patients with pleural mesothelioma cancer will benefit (and which will not) from promising immunotherapy…
Read More
Winter Storm Delays Cancer Treatment Across U.S.
- by Sean Marchese
- Treatment & Doctors
- Feb 22, 2021
Severe winter storms have affected multiple central U.S. states with power outages and water supply disruptions. State officials in Texas, Louisiana and Mississippi say restoring power to everyone could still…
Read More
FDA Fast-Tracks Mesothelioma Vaccine Development
- by Tim Povtak
- Research & Clinical Trials
- Feb 19, 2021
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected…
Read More
Research Reinforces Gene Mutation Links to Mesothelioma
- by Tim Povtak
- Research & Clinical Trials
- Feb 11, 2021
More than ever, Dr. Michele Carbone at the University of Hawaii Cancer Center believes early testing for genetic mutations can lead to fewer cases of malignant mesothelioma and a…
Read More
Mesothelioma Still Prevalent in Canada Following Asbestos Ban
- by Tim Povtak
- Asbestos Exposure & Bans
- Feb 8, 2021
More than two years after implementing a much-celebrated ban of asbestos, Canadians have come to realize the real fight has only just begun. Malignant mesothelioma cancer isn’t going…
Read More
Opdivo Study Offers Hope to Relapsed Mesothelioma Patients
- by Tim Povtak
- Research & Clinical Trials
- Feb 4, 2021
A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and progression-free survival. Nivolumab, also…
Read More
Researchers: Mesothelioma Trials Need More Inclusive Criteria
- by Tim Povtak
- Research & Clinical Trials
- Feb 2, 2021
Clinical trials for mesothelioma need more inclusive criteria to better reflect the patients being seen at major cancer treatment centers, according to a recent study conducted in Sydney,…
Read More
EPA’s Asbestos Risk Evaluation Faces Litigation
- by Tim Povtak
- Legislation & Litigation
- Jan 27, 2021
The Asbestos Disease Awareness Organization continued its challenge of the U.S. Environmental Protection Agency, filing a petition for review Jan. 26 in the U.S. Court of…
Read More
Study: Mesothelioma Survival Rates Rise with SMART Protocol
- by Tim Povtak
- Research & Clinical Trials
- Jan 21, 2021
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a larger clinical trial at…
Read More
